189 related articles for article (PubMed ID: 15279597)
1. Recent development in the field of dual COX / 5-LOX inhibitors.
Julémont F; Dogné JM; Pirotte B; de Leval X
Mini Rev Med Chem; 2004 Aug; 4(6):633-8. PubMed ID: 15279597
[TBL] [Abstract][Full Text] [Related]
2. New trends in dual 5-LOX/COX inhibition.
Leval Xd; Julemont F; Delarge J; Pirotte B; Dogne JM
Curr Med Chem; 2002 May; 9(9):941-62. PubMed ID: 11966455
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Shrivastava SK; Srivastava P; Bandresh R; Tripathi PN; Tripathi A
Bioorg Med Chem; 2017 Aug; 25(16):4424-4432. PubMed ID: 28669741
[TBL] [Abstract][Full Text] [Related]
4. Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve.
Le Filliatre G; Sayah S; Latournerie V; Renaud JF; Finet M; Hanf R
Br J Pharmacol; 2001 Apr; 132(7):1581-9. PubMed ID: 11264253
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.
Sud'ina GF; Pushkareva MA; Shephard P; Klein T
Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):99-108. PubMed ID: 18280718
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A₂, cyclooxygenases, lipoxygenase and proinflammatory cytokines.
Bukhari SN; Lauro G; Jantan I; Bifulco G; Amjad MW
Bioorg Med Chem; 2014 Aug; 22(15):4151-61. PubMed ID: 24938495
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
Celotti F; Laufer S
Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
[TBL] [Abstract][Full Text] [Related]
8. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed multitarget agents against inflammation and pain.
Hwang SH; Wecksler AT; Wagner K; Hammock BD
Curr Med Chem; 2013; 20(13):1783-99. PubMed ID: 23410172
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of N-difluoromethyl-1,2-dihydropyrid-2-one acetic acid regioisomers: dual inhibitors of cyclooxygenases and 5-lipoxygenase.
Yu G; Praveen Rao PN; Chowdhury MA; Abdellatif KR; Dong Y; Das D; Velázquez CA; Suresh MR; Knaus EE
Bioorg Med Chem Lett; 2010 Apr; 20(7):2168-73. PubMed ID: 20202839
[TBL] [Abstract][Full Text] [Related]
11. Regulation of COX and LOX by curcumin.
Rao CV
Adv Exp Med Biol; 2007; 595():213-26. PubMed ID: 17569213
[TBL] [Abstract][Full Text] [Related]
12. JJK694, a synthesized obovatol derivative, inhibits platelet activation by suppressing cyclooxygenase and lipoxygenase activities.
Yu JY; Lee JJ; Jung JK; Min YK; Kim TJ; Ma JY; Lee MY; Yun YP
Biosci Biotechnol Biochem; 2012; 76(11):2038-43. PubMed ID: 23132562
[TBL] [Abstract][Full Text] [Related]
13. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
14. Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
Li Y; Chen SH; Ou TM; Tan JH; Li D; Gu LQ; Huang ZS
Bioorg Med Chem; 2011 Mar; 19(6):2074-83. PubMed ID: 21349729
[TBL] [Abstract][Full Text] [Related]
15. Anti-platelet activity of diacetylated obovatol through regulating cyclooxygenase and lipoxygenase activities.
Yu JY; Lee JJ; Jung JK; Min YK; Ma JY; Kim TJ; Lee MY; Yun YP
Arch Pharm Res; 2012 Dec; 35(12):2191-8. PubMed ID: 23263814
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
[TBL] [Abstract][Full Text] [Related]
17. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase.
Shabaan MA; Kamal AM; Faggal SI; Elsahar AE; Mohamed KO
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900308. PubMed ID: 32031284
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors.
Cusan C; Spalluto G; Prato M; Adams M; Bodensieck A; Bauer R; Tubaro A; Bernardi P; Da Ros T
Farmaco; 2005 Apr; 60(4):327-32. PubMed ID: 15848208
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cell-substrate adhesion by the lipoxygenase and cyclooxygenase branches of arachidonic acid metabolism.
Roberts LA; Glenn HL; Whitfield RA; Jacobson BS
Adv Exp Med Biol; 2002; 507():525-9. PubMed ID: 12664635
[No Abstract] [Full Text] [Related]
[Next] [New Search]
